By Fineline Cube Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing round. The funding will support the clinical development of its receptor interacting protein kinase 1 (RIPK1) inhibitor and expansion of its R&D pipeline targeting age-related degenerative diseases.
Funding Round Details
The financing round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors such as Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, and K2 Venture Partners. New investors include MSA Capital, CBC Group, Long River Investments, LSV Capital, Superstring Capital, Future Innovation Fund, and a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA).
Company Background and Pipeline
Founded in 2017, Sironax focuses on novel treatments for age-related degenerative diseases. Its pipeline includes programs targeting regulated cell death, neuroprotective pathways, and neuroinflammation. The company is currently conducting early clinical studies with SIR0365 and SIR2446 and has ongoing preclinical research.-Fineline Info & Tech